Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 14/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.52 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.51 |
| ▸ | F10 | P00742 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4578145 | 0.85 | HDAC1 (0.64) | HDAC1HDAC3KCNH2HDAC2 | |
| SCHEMBL4580174 | 0.85 | HDAC1 (0.64) | HDAC1HDAC3KCNH2HIF1AEPAS1 | |
| SCHEMBL4578900 | 0.84 | HDAC1 (0.70) | HDAC1HDAC3KCNH2RAB9ANPC1 | |
| SCHEMBL4579730 | 0.84 | HDAC1 (0.79) | HDAC1HDAC3RAB9AHIF1AEPAS1 | |
| SCHEMBL4579920 | 0.84 | HDAC1 (0.67) | HDAC1HDAC3KCNH2RAB9ANPC1 | |
| SCHEMBL4578211 | 0.82 | HDAC2 (0.62) | HDAC1HDAC3KCNH2RAB9ANPC1 | |
| SCHEMBL4579854 | 0.81 | HDAC1 (0.57) | HDAC1HDAC3KCNH2RAB9AHIF1A | |
| SCHEMBL4580158 | 0.81 | HDAC1 (0.63) | HDAC1HDAC3KCNH2RAB9AHIF1A | |
| SCHEMBL4578865 | 0.81 | NPC1 (0.68) | HDAC1HDAC3KCNH2RAB9ANPC1 | |
| SCHEMBL4578653 | 0.81 | HDAC1 (0.70) | HDAC1HDAC3KCNH2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007720-B1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2013-12-25 | — | — | EP | disclosed |
| US-8598168-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2013-12-03 | — | — | US | disclosed |
| EP-2007720-A1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2008-12-31 | — | — | EP | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| WO-2007118137-A1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | HDAC1 1/4885HDAC3 3/4885KCNH2 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.